Monitor the November FDA meeting outcome for potential pediatric expansion of the Rett syndrome Phase 3 trial. Full PK/safety data readouts from the ADME/DDI studies could support regulatory filings but no timeline for data release was provided.
Price Chart
Executive Summary
Anavex announced completion of clinical conduct for two blarcamesine pharmacology studies (ADME and DDI) in healthy volunteers, with no serious adverse events reported. The company also highlighted FDA clearance of its IND for Fragile X syndrome and an upcoming November FDA meeting to discuss adding pediatric participants to the Phase 3 Rett syndrome study. This is a routine pipeline progress update with no financial data or binary catalyst — a modest operational milestone for a clinical-stage biotech.
Key Facts
- Clinical conduct of ADME (8 participants) and DDI (65 participants) studies of blarcamesine completed; all received 30 mg dose
- No serious adverse events reported in either study; full safety and PK analysis ongoing
- FDA cleared IND for blarcamesine in Fragile X syndrome (announced Oct 15, 2026)
- FDA meeting scheduled for November 2026 to discuss adding pediatric participants to Phase 3 Rett syndrome study
- Blarcamesine has Orphan Drug Designation for both Rett syndrome and Fragile X syndrome
Financial Impact
No financial figures disclosed; clinical-stage company with no revenue or earnings data in this filing
Risk Factors
- Clinical-stage biotech with no approved products; all programs are pre-revenue
- Full safety and pharmacokinetic data analysis still ongoing — preliminary observations only
- FDA meeting in November is a discussion, not a guaranteed approval for protocol amendment
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001731122-26-001351 |
| Document: e8011_ex99-1.htm | 0001731122-26-001351 |
| Document: 0001731122-26-001351-index-headers.html | 0001731122-26-001351 |
| Document: 0001731122-26-001351-index.html | 0001731122-26-001351 |
| Document: 0001731122-26-001351.txt | 0001731122-26-001351 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $1.36 | awaiting T+60 | — | $1.33 (−2.21%) |
Oct 20, 2026 6d ago | Press Release | $1.36 | awaiting T+60 | — | $1.33 (−2.21%) |
Oct 15, 2026 11d ago | 8-K | $1.31 | awaiting T+60 | — | $1.33 (+1.53%) |
Oct 15, 2026 11d ago | Press Release | $1.31 | awaiting T+60 | — | $1.33 (+1.53%) |
Sep 28, 2026 28d ago | 8-K | $2.36 | awaiting T+60 | — | $1.33 (−43.64%) |
Sep 17, 2026 5w ago | DFAN14A | $2.41 | awaiting T+60 | — | $1.33 (−44.81%) |
Sep 15, 2026 5w ago | DFAN14A | $2.44 | awaiting T+60 | — | $1.33 (−45.49%) |
Sep 14, 2026 6w ago | DEFA14A | $2.60 | awaiting T+60 | — | $1.33 (−48.85%) |
Sep 4, 2026 7w ago | DEFA14A | $2.85 | awaiting T+60 | — | $1.33 (−53.33%) |
Sep 3, 2026 7w ago | DFAN14A | $2.86 | awaiting T+60 | — | $1.33 (−53.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers